Combination therapy of carbon dioxide laser with topical halometason cream and 308 nm excimer laser for the treatment of vitiligo: an optimized combined treatment protocol.
4 affiliations
- 1Department of Aesthetic and Plastic Surgery, Peking University International Hospital, No. 1 Life Park Road, Life Science Park of Zhongguancun, Changping District, Beijing, 102206, China.
- 2Department of Dermatology, The First Affiliated Hospital of Dalian Medical University, Dalian, 116021, China.
- 3Department of Dermatology, Republic of Sakha Yakutia, Yakutsk, 677000, Russian Federation.
- 4Department of Dermatology, The First Affiliated Hospital of Dalian Medical University, Dalian, 116021, China. [email protected].
Abstract
The treatment for refractory non-segmental vitiligo (RNSV) remains unsatisfactory, particularly for acral vitiligo (AV) and phototherapy platform-stage vitiligo (PPV), despite the numerous treatment modalities available for vitiligo. The efficacy of a triple combination therapy comprising a 308-nm excimer lamp, a fractional CO₂ laser, and a topical formulation was examined in this study. A better topical formulation and fractional CO₂ laser settings were tested on 64 fresh human foreskin samples. At 15 mJ pulse energy and 10% coverage, the fractional CO₂ laser and topical halometasone cream achieved a more widespread and consistent distribution with minimal side effects. The clinical trial included 98 individuals with 158 RNSV lesions. A total of 46 patients with 98 AV lesions and 52 with 60 PPV lesions were randomly assigned to T and C groups. T groups received fractional CO₂ laser, plastic-wrapped halometasone cream, and 308-nm excimer lamp therapy. The C group received 308-nm excimer lamp, topical calcineurin inhibitor and halometasone cream (without fractional CO₂ laser). A twice-weekly 308-nm excimer lamp therapy was used for three months. In the T group of PPV, 50% of lesions were successful at the conclusion of the research, while only 10% of lesions in the C group of PPV were successful (P ≤ 0.000). Success was attained by 8.16% of lesions in the T group of AV, while only 6.12% of lesions in the C group of AV were successful (P = 0.425). The PPV is definitively influenced by the tripartite combination therapy of a 308-nm excimer lamp, topical halometasone cream, and fractional CO₂ laser. The treatment duration of PPV can be shortened and the phototherapy platform stage can be avoided. Conversely, the combination treatment did not yield satisfactory results for vitiligo in the acral region.
Related
- The Safety of Melasma Treatment in Vitiligo Patients: An International E‐Delphi Study
- Azospirillum brasilense and cytidine as combination treatment to enhance drought resilience of peas
- Healthcare Providers’ Perspectives on Nonsegmental Vitiligo Severity, Patient Impact, and Treatment Gaps in the United States and Europe
- IOP-independent treatment for neurodegeneration in glaucoma using optimized ROS-scavenging microparticles for sustained release of erythropoietin
- Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies
BibTeX
@article{yang2026combination,
title = {{Combination therapy of carbon dioxide laser with topical halometason cream and 308 nm excimer laser for the treatment of vitiligo: an optimized combined treatment protocol.}},
author = {Yi Yang and Molu Ozukum and Weiyi Zou and Xin Zheng and Shixin Han and Anna Nikiforova and Zhiqi Song},
journal = {Lasers in medical science},
year = {2026},
month = oct,
doi = {10.1007/s10103-026-05076-z},
url = {https://europepmc.org/article/MED/42925430},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Combination therapy of carbon dioxide laser with topical halometason cream and 308 nm excimer laser for the treatment of vitiligo: an optimized combined treatment protocol.
AU - Yi Yang
AU - Molu Ozukum
AU - Weiyi Zou
AU - Xin Zheng
AU - Shixin Han
AU - Anna Nikiforova
AU - Zhiqi Song
PY - 2026
DA - 2026/10/24
JO - Lasers in medical science
DO - 10.1007/s10103-026-05076-z
UR - https://europepmc.org/article/MED/42925430
AB - The treatment for refractory non-segmental vitiligo (RNSV) remains unsatisfactory, particularly for acral vitiligo (AV) and phototherapy platform-stage vitiligo (PPV), despite the numerous treatment modalities available for vitiligo. The efficacy of a triple combination therapy comprising a 308-nm excimer lamp, a fractional CO₂ laser, and a topical formulation was examined in this study. A better topical formulation and fractional CO₂ laser settings were tested on 64 fresh human foreskin samples. At 15 mJ pulse energy and 10% coverage, the fractional CO₂ laser and topical halometasone cream achieved a more widespread and consistent distribution with minimal side effects. The clinical trial included 98 individuals with 158 RNSV lesions. A total of 46 patients with 98 AV lesions and 52 with 60 PPV lesions were randomly assigned to T and C groups. T groups received fractional CO₂ laser, plastic-wrapped halometasone cream, and 308-nm excimer lamp therapy. The C group received 308-nm excimer lamp, topical calcineurin inhibitor and halometasone cream (without fractional CO₂ laser). A twice-weekly 308-nm excimer lamp therapy was used for three months. In the T group of PPV, 50% of lesions were successful at the conclusion of the research, while only 10% of lesions in the C group of PPV were successful (P ≤ 0.000). Success was attained by 8.16% of lesions in the T group of AV, while only 6.12% of lesions in the C group of AV were successful (P = 0.425). The PPV is definitively influenced by the tripartite combination therapy of a 308-nm excimer lamp, topical halometasone cream, and fractional CO₂ laser. The treatment duration of PPV can be shortened and the phototherapy platform stage can be avoided. Conversely, the combination treatment did not yield satisfactory results for vitiligo in the acral region.
SN - 0268-8921
SN - 1435-604X
ER -